Comparison of serum neuropeptide-ff and catestatin levels in hypertensive pregnant women
- 1 July 2024
- journal article
- research article
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 15 (7) , 495-499
Abstract
Aim We aimed to compare the levels of Neuropeptide-FF and Catestatin in the sera of hypertensive and normotensive pregnant women, to determine the possible changes in hypertensive diseases of pregnancy and to examine the possible place of pregnancy in hypertensive diseases. Methods We used the quantitative analysis method to test the hypotheses of the research and examine the relationship between variables. Neuropeptide FF and Catestatin levels were analyzed by Enzyme Linked Immunoassay (ELISA) method. Neuropeptide-FF and Catestatin values of patient and control groups were analyzed with Mann-Whitney and Chi-square tests. Results A higher Catestatin value was determined in the patient group compared to the control group, and this difference was statistically significant(P < .001). Catestatin value in the patient group was 31.61 ± 12.54, and value in the control group was 48.46 ± 22.45 and the relation was statistically found significant (P < .05). The neuropeptide-FF was not statistically significant in the patient and control group compared to the control group (P = .916). Therefore, the Neuropeptide-FF value in the patient group was 134.30 ± 93.72; this value was found as 139.49 ± 96.41 in the control group, but the relation statistically was not found significant (P > .05). According to the analysis results of our study, a statistically significant difference was found for Catestatin at the 5% significance level between the patient group and the control group. Conclusion Decreased NPFF expression in the hypothalamus of hypertensive patients may lead to impaired interaction with other neurochemical systems and therefore may play a role in the pathogenesis of hypertensive disease.Keywords
This publication has 15 references indexed in Scilit:
- Catestatin Gly364Ser Variant Alters Systemic Blood Pressure and the Risk for Hypertension in Human Populations via Endothelial Nitric Oxide PathwayHypertension, 2016
- The hypothalamic neuropeptide FF network is impaired in hypertensive patientsBrain and Behavior, 2014
- Novel Peptide Isomer Strategy for Stable Inhibition of Catecholamine ReleaseHypertension, 2012
- Regulation of catecholamine release in human adrenal chromaffin cells by β-adrenoceptorsNeurochemistry International, 2012
- Direct Vasoactive Effects of the Chromogranin A (CHGA) Peptide Catestatin in HumansIn VivoClinical and Experimental Hypertension, 2010
- Prolactin‐releasing peptide effects in the rat brain are mediated through the Neuropeptide FF receptorEuropean Journal of Neuroscience, 2009
- Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressureCardiovascular Research, 2008
- Catecholamine Release–Inhibitory Peptide Catestatin (Chromogranin A 352–372 )Circulation, 2007
- Neuropeptide FF and neuropeptide VF inhibit GABAergic neurotransmission in parvocellular neurons of the rat hypothalamic paraventricular nucleusAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2007
- Neuropeptide FF (NPFF) control of magnocellular neurosecretory cells of the rat hypothalamic paraventricular nucleus (PVN)Peptides, 2006